

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Alexa Fluor(R) 700 anti-human CD38

RRID:AB_2072781

Type: Antibody

Proper Citation

BioLegend Cat# 303524, RRID:AB_2072781

Antibody Information

URL: http://antibodyregistry.org/AB_2072781

Proper Citation: BioLegend Cat# 303524, RRID:AB_2072781

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, SB

Antibody Name: Alexa Fluor(R) 700 anti-human CD38

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: Clone HIT2

Antibody ID: AB_2072781

Vendor: BioLegend

Catalog Number: 303524

Alternative Catalog Numbers: 303523

Record Creation Time: 20231110T050619+0000

Record Last Update: 20260829T053949+0000

Ratings and Alerts

- This antibody has been included in the HuBMAP's Organ Mapping Antibody Panels, please see specific validation data: <https://avr.hubmapconsortium.org> See: Human_Lymph_Node_Manual_IBEX.xlsx - The Human BioMolecular Atlas Program <https://humanatlas.io/omap>

No alerts have been found for Alexa Fluor(R) 700 anti-human CD38.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Dodd KC, et al. (2026) Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis. Med (New York, N.Y.), 7(3), 100987.

Ismail J, et al. (2026) Single-cell transcriptomics reveal altered B cell responses and T cell senescence in geriatric non-responders to COVID-19 mRNA vaccination. iScience, 29(5), 115730.

Armani-Tourret M, et al. (2024) Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon- γ 2a. Cell, 187(5), 1238.

Pelletier AN, et al. (2024) A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine. Cell reports, 43(7), 114370.

Lederhofer J, et al. (2024) Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity, 57(3), 574.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.